Fluorocyclopentenylcytosine

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameFluorocyclopentenylcytosine
Drug Alias NameRoducitabine (Ocuphire Pharma)NGC-GemcitabineFCPECRX-3117TV-1360 +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionCyclin-dependent kinase inhibitorsDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsCyclin-dependent kinaseDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRexahn Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiosense Global LLCProcessa Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A